CSPC Pharmaceutical Group Limited (CHJTF) Stock Price & Analysis
CSPC Pharmaceutical Group Limited (CHJTF) closed at USD 1.26 on Wednesday, October 21, 2026, up 13.51% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.11; the Oct 21, 2026 session ranged USD 1.26–1.26 on volume of 2,000 shares. Market capitalization is $14.37B, with a 52-week range of USD 0.94–1.39 (PNK). Source: Nexqual, retrieved October 23, 2026 at 16:42 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CHJTF.md
Key facts (CHJTF)
- Analysts: None.
- Total return with dividends: 1Y +17.9% vs S&P 500 +14.6%; 5Y +22.6% vs S&P 500 +77.3%.
- Next earnings: 2026-11-19, EPS estimate USD —, revenue estimate $7.66B.
Analysts (CHJTF)
Consensus None.
Total return (dividends reinvested) (CHJTF)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +17.9% | +22.6% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | +18.0% | +4.2% |
| Volatility (annualized) | 36.4% | 48.1% |
| Max drawdown | -29.5% (Feb 2026→Jun 2026) | -54.2% (Jan 2022→Sep 2024) |
CHJTF analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $7.66B | — |
| Next quarter (ends Dec 2026) | — | — | — | $7.56B | — |
| Current fiscal year (ends Dec 2026) | — | — | — | $38.49B | — |
| Next fiscal year (ends Dec 2027) | — | — | — | $35.70B | — |
Key Statistics (as of October 23, 2026 at 16:42 UTC)
| Price | USD 1.26 |
|---|---|
| Change | ▲ 13.51% (up) |
| Previous Close | USD 1.11 |
| Open | USD 1.26 |
| Day Range | USD 1.26 – 1.26 |
| 52-Week Range | USD 0.94 – 1.39 |
| Volume | 2,000 shares |
| Market Cap | $14.37B |
| Exchange | PNK |
Technical Analysis (CHJTF)
Nexqual's technical model rates CHJTF "BUY" based on 6 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 16:42 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 1.11) |
| MACD | 0 (positive) |
Analyst Ratings (CHJTF)
Wall Street analysts rate CHJTF "None", per Nexqual as of October 23, 2026 at 16:42 UTC.
| Consensus Rating | None |
|---|
Earnings (CHJTF)
| Next Earnings Date | 2026-11-19 |
|---|---|
| Revenue Estimate | $7.66B |
Source: Nexqual, October 23, 2026 at 16:42 UTC.
Financials & Fundamentals (CHJTF)
| Total Revenue | $31.33B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +93.80% |
| Gross Margin | +71.85% |
| Operating Margin | +52.59% |
| Profit Margin | +23.71% |
| ROE | +20.90% |
| Debt / Equity | 0.02 |
| Current Ratio | 2.14 |
| Total Cash | $18.42B |
| Total Debt | $652.49M |
Source: Nexqual, October 23, 2026 at 16:42 UTC.
Financial Health Score (CHJTF)
Nexqual rates CSPC Pharmaceutical Group Limited's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 16:42 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 53% (last 12 months) |
| Balance Sheet | Strong — CNY 18.4B cash vs CNY 652M debt, net cash position |
| Cash Flow | Solid — Operating cash flow CNY 13.5B (TTM) |
| Efficiency | Strong — ROE 21%, ROA 10.7% |
Ownership (CHJTF)
| Insider Ownership | +32.58% |
|---|---|
| Institutional Ownership | +37.43% |
| Shares Outstanding | 11.41B |
| Float | 7.63B |
Source: Nexqual, October 23, 2026 at 16:42 UTC.
Leadership (CHJTF)
CSPC Pharmaceutical Group Limited is led by Lei Cai, CEO & Vice Chairman of the Board, per Nexqual as of October 23, 2026 at 16:42 UTC.
| CEO & Vice Chairman of the Board | Lei Cai |
|---|---|
| Executive Chairman | Dongchen Cai |
| COO & Vice-Chairman of the Board | Qingjie Wei |
| Executive Director & Chief Scientist | Chunlei Li |
| Executive Director | Zhenguo Wang |
Major Backers & Investors (CHJTF)
Notable institutional backers of CSPC Pharmaceutical Group Limited include American Century ETF Trust-Avantis Emerging Markets Equity ETF, DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT., Fidelity, according to Nexqual as of October 23, 2026 at 16:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century ETF Trust-Avantis Emerging Markets Equity ETF | 0.49% |
| DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT. | 0.43% |
| Fidelity | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.07% |
| BlackRock | 1.11% |
| State Street | 0.11% |
Source: Nexqual, October 23, 2026 at 16:42 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIIB | Biogen Inc. | USD 250.88 | ▼ 1.17% |
| GRFS | Grifols, S.A. | USD 7.55 | ▲ 1.28% |
| OGN | Organon & Co. | USD 13.76 | ▲ 0.04% |
| SNY | Sanofi | USD 41.51 | ▼ 1.07% |
| GSK | GSK plc | USD 50.66 | ▼ 1.07% |
| BMY | Bristol-Myers Squibb Company | USD 61.82 | ▼ 1.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:42 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt